Massachusetts is currently home to 3159 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
NCT06744205
Recruiting
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/02/2025
Locations: Boston Clinical Trials- Site Number : 8400009, Boston, Massachusetts
Conditions: Influenza, Healthy Volunteers
Register for Updates
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236
Recruiting
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Dana Farber/Harvard Cancer Center, Boston, Massachusetts
Conditions: Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
Register for Updates
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
NCT06710548
Recruiting
The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Ovarian Cancer, Advanced Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Cancer, PARP Inhibitor, Fatigue Related to Cancer Treatment, Fatigue in Cancer Survivors
Register for Updates
Use of a Colorectal Cancer Screening Decision Support Tool in Primary Care
NCT06625983
Recruiting
The research question we pose is, Does a colorectal cancer (CRC) screening decision support tool offered in advance of primary care visits increase CRC screening completion rates? Our work aims to answer this question by evaluating the effectiveness of an MGB decision support tool to 1) promote informed decisions about CRC screening for average risk patients ages 45-75, 2) deploy a decision support tool as part of a primary care bundle questionnaire, and 3) support patients in completing their p... Read More
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
04/02/2025
Locations: Mass General Brigham, Boston, Massachusetts
Conditions: Colorectal Cancer Control and Prevention, Colorectal Cancer Screening, Shared Decision Making, Decision Aid
Register for Updates
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201
Recruiting
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Sclerosis, Myasthenia Gravis
Register for Updates
mTBI Identification and Monitoring Through Retinal Scanning
NCT06142435
Recruiting
Rebion has developed a device, the Rebion trauma tool (referred to as the head and intraocular trauma tool, or "HITT"), that detects ocular fixation and alignment using a binocular retinal scan. Preliminary data obtained from hospitalized patients with a clinically-confirmed traumatic brain injury (TBI) and uninjured controls indicates that the device can detect changes in ocular fixation, alignment, and saccades that are related to brain injury. This study seeks to evaluate the ability of the R... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
04/02/2025
Locations: Boston Medical Center Concussion Clinic, Ryan Center for Sports Medicine & Rehabilitation at Boston University, Boston, Massachusetts
Conditions: Brain Injuries, Traumatic
Register for Updates
Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis
NCT06123481
Recruiting
Osteonecrosis of the femoral head (ONFH) is a debilitating musculoskeletal disease that is characterized by localized death of bone cells and associated cellular elements within the subchondral bone. If it progresses, it results in the collapse of the femoral head (ball part of the hip) giving rise to secondary arthritis. This condition is associated with marked pain and loss of function, often necessitating a joint replacement. Due to the relatively young age of onset of ONFH (often in 20s and... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Osteonecrosis of the Femoral Head, Avascular Necrosis of the Femoral Head
Register for Updates
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
NCT06102005
Recruiting
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2025
Locations: Brigham & Women's Hospital- Site Number : 8400034, Boston, Massachusetts
Conditions: Asthma
Register for Updates
Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery
NCT06101745
Recruiting
The goal of this clinical trial is to determine if the drug Nizaracianine Triflutate can help surgeons see and avoid the ureters during abdominopelvic surgery. The ureters are thin-wall, collapsible tubes that connect the kidneys to the bladder. They are difficult to see during surgery and are sometimes damaged accidentally. The main questions to answer are: 1) is this drug safe for use in patients undergoing abdominopelvic surgery and 2) can the drug see the ureters while simultaneously providi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts
Conditions: Injury of Ureter During Surgery (Disorder)
Register for Updates
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
NCT06101095
Recruiting
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. Duration of study period (per participant) * Screening period: Up to 12 weeks before Week 0 * Randomized double-blind period: 24 weeks *... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Massachusetts Chan Medical School- Site Number : 8400019, Worcester, Massachusetts
Conditions: Eosinophilic Oesophagitis
Register for Updates
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
NCT06042257
Recruiting
The purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children 6-12 years of age with Down syndrome (DS) after 8 weeks of treatment.
Gender:
ALL
Ages:
Between 6 years and 12 years
Trial Updated:
04/02/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589
Recruiting
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
04/02/2025
Locations: Research Site, Boston, Massachusetts
Conditions: Asthma
Register for Updates